These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 9250408)

  • 1. Oxidation of low-density lipoproteins produces levuglandin-protein adducts.
    Salomon RG; Subbanagounder G; Singh U; O'Neil J; Hoff HF
    Chem Res Toxicol; 1997 Jul; 10(7):750-9. PubMed ID: 9250408
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protein adducts of iso[4]levuglandin E2, a product of the isoprostane pathway, in oxidized low density lipoprotein.
    Salomon RG; Sha W; Brame C; Kaur K; Subbanagounder G; O'Neil J; Hoff HF; Roberts LJ
    J Biol Chem; 1999 Jul; 274(29):20271-80. PubMed ID: 10400646
    [TBL] [Abstract][Full Text] [Related]  

  • 3. (Carboxyalkyl)pyrroles in human plasma and oxidized low-density lipoproteins.
    Kaur K; Salomon RG; O'Neil J; Hoff HF
    Chem Res Toxicol; 1997 Dec; 10(12):1387-96. PubMed ID: 9437530
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Iso[7]LGD2-protein adducts are abundant in vivo and free radical-induced oxidation of an arachidonyl phospholipid generates this D series isolevuglandin in vitro.
    Poliakov E; Meer SG; Roy SC; Mesaros C; Salomon RG
    Chem Res Toxicol; 2004 May; 17(5):613-22. PubMed ID: 15144218
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Levuglandin E2-protein adducts in human plasma and vasculature.
    Salomon RG; Subbanagounder G; O'Neil J; Kaur K; Smith MA; Hoff HF; Perry G; Monnier VM
    Chem Res Toxicol; 1997 May; 10(5):536-45. PubMed ID: 9168251
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Formation and stability of pyrrole adducts in the reaction of levuglandin E2 with proteins.
    DiFranco E; Subbanagounder G; Kim S; Murthi K; Taneda S; Monnier VM; Salomon RG
    Chem Res Toxicol; 1995; 8(1):61-7. PubMed ID: 7703368
    [TBL] [Abstract][Full Text] [Related]  

  • 7. C-reactive protein inhibits in vitro oxidation of low-density lipoprotein.
    Rufail ML; Ramage SC; van Antwerpen R
    FEBS Lett; 2006 Oct; 580(22):5155-60. PubMed ID: 16962105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Macrophage recognition of LDL modified by levuglandin E2, an oxidation product of arachidonic acid.
    Hoppe G; Subbanagounder G; O'Neil J; Salomon RG; Hoff HF
    Biochim Biophys Acta; 1997 Jan; 1344(1):1-5. PubMed ID: 9022751
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Measurement of oxidation in plasma Lp(a) in CAPD patients using a novel ELISA.
    Podrez EA; O'Neil J; Salomon RG; Schreiber MJ; Hoff HF
    Kidney Int; 1998 Aug; 54(2):637-45. PubMed ID: 9690232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Contribution of superoxide to reduced antioxidant activity of glycoxidative serum albumin.
    Sakata N; Moh A; Takebayashi S
    Heart Vessels; 2002 Nov; 17(1):22-9. PubMed ID: 12434198
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assays for acetaldehyde-derived adducts in blood proteins based on antibodies against acetaldehyde/lipoprotein condensates.
    Latvala J; Melkko J; Parkkila S; Järvi K; Makkonen K; Niemelä O
    Alcohol Clin Exp Res; 2001 Nov; 25(11):1648-53. PubMed ID: 11707639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Secondary radicals derived from chloramines of apolipoprotein B-100 contribute to HOCl-induced lipid peroxidation of low-density lipoproteins.
    Hazell LJ; Davies MJ; Stocker R
    Biochem J; 1999 May; 339 ( Pt 3)(Pt 3):489-95. PubMed ID: 10215584
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunochemical characterization of purified human oxidized low-density lipoprotein antibodies.
    Virella G; Koskinen S; Krings G; Onorato JM; Thorpe SR; Lopes-Virella M
    Clin Immunol; 2000 May; 95(2):135-44. PubMed ID: 10779407
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibodies made against a formaldehyde-protein adduct cross react with an acetaldehyde-protein adduct. Implications for the origin of antibodies in human serum which recognize acetaldehyde-protein adducts.
    Pietrzak ER; Shanley BC; Kroon PA
    Alcohol Alcohol; 1995 May; 30(3):373-8. PubMed ID: 7545992
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of oxidation on the structure and stability of human low-density lipoprotein.
    Jayaraman S; Gantz DL; Gursky O
    Biochemistry; 2007 May; 46(19):5790-7. PubMed ID: 17444660
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oxidation and antioxidation of human low-density lipoprotein and plasma exposed to 3-morpholinosydnonimine and reagent peroxynitrite.
    Thomas SR; Davies MJ; Stocker R
    Chem Res Toxicol; 1998 May; 11(5):484-94. PubMed ID: 9585479
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PGF2-isoprostanes formed during copper-induced oxidation of low-density lipoproteins are the prostaglandins that cross-react with PGE2 antibodies.
    Proudfoot JM; Beilin LJ; Croft KD
    Biochem Biophys Res Commun; 1995 Jan; 206(2):455-61. PubMed ID: 7826362
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of dietary oxidized cholesterol and oxidized fatty acids in the development of atherosclerosis.
    Staprans I; Pan XM; Rapp JH; Feingold KR
    Mol Nutr Food Res; 2005 Nov; 49(11):1075-82. PubMed ID: 16270280
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Probabilistic kinetic model of slow oxidation of low-density lipoprotein: I. Theory.
    Herak JN; Stojanović N; Krilov D
    Chem Phys Lipids; 2004 Apr; 129(1):63-74. PubMed ID: 14998728
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low-density lipoprotein oxidation.
    Iuliano L; Micheletta F; Violi F
    Ital Heart J; 2001 Dec; 2(12):867-72. PubMed ID: 11838329
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.